Immunoassay Analysis of Kanamycin in Serum Using the Tobramycin Kit
ABSTRACT Kanamycin is one of the aminoglycosides used in the treatment of multidrug resistant tuberculosis. Blood concentrations of kanamycin are predictive for the treatment efficacy and the occurrence of side effects and dose adjustments can be needed to optimize therapy. However, an immunoassay method for the quantification of kanamycin is not commercially available.
We modified the existing tobramycin immunoassay to analyse kanamycin. This modified method was tested in a concentration range of 0.3 -80.0 mg/L for inaccuracy and imprecision. In addition, the analytical results of the immunoassay method were compared to an LC-MS/MS analytical method using Passing and Bablok regression.
Within-day imprecision varied between from 2.3 -13.3% and between day imprecision ranged from 0.0 -11.3%. The inaccuracy ranged from -5.2 -7.6%. No significant cross-reactivity with other antimicrobials and antiviral agents was observed. The results of the modified immunoassay method were comparable with the LC-MS/MS analytical outcome. This new immunoassay method enables laboratories to perform therapeutic drug monitoring of kanamycin without the need of complex and expensive LC-MS/MS equipment.
BACKGROUND
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. Unfortunately, resistance to the two first-line drugs in TB treatment, isoniazid and rifampin, is emerging. 1 Treatment regimens for multidrug resistant TB (MDR-TB) includes a quinolone and an injectable; amikacin, kanamycin or capreomycin. 2 Unfortunately, the use of aminoglycosides comes with toxicity such as renal failure and irreversible hearing loss. 3 Recently, a study in MDR-TB patients showed that the toxicity of aminoglycosides was correlated with the cumulative area under the curve. 4 For efficacy, it is well recognized that the top serum concentration (C max ) is related to the efficacy of aminoglycosides. 5 In addition, pharmacokinetic guided dosing reduced the daily dose of aminoglycosides with excellent treatment outcome. 6 This indicates that serum concentration monitoring may be of added value in the treatment of tuberculosis. The targeted peak concentration for kanamycin in MDR-TB is 20-30 mg/L, while the trough concentration should be as low as reasonably achievable in order to prevent toxicity. 7 Although analytical methods to quantify the serum or plasma concentrations of amikacin and kanamycin using liquid chromatography tandem mass spectrometry (LC-MS/MS) have been described, this technique is commonly not available in most developing countries. [8] [9] [10] [11] [12] However, in contrast to amikacin no commercially available analytical immunoassay kit is available to analyse kanamycin.
Kanamycin is more structurally related to tobramycin than to amikacin (figure 1). The product insert of the immunoassay kit of tobramycin, based on the enzyme multiplied immunoassay technique (EMIT), indicates cross-reactivity for kanamycin. 13 We therefore explored the possibilities to analyse kanamycin serum concentration with the tobramycin immunoassay kit.
MATERIALS AND METHODS

Materials
An Architect c8000 (Abbott Diagnostics, IL, USA) was used to perform the analysis. The tobramycin kit (Syva Emit 2000 Tobramycin Assay, art. no REF 4S019UL, batches 4S019UL-G2 and 4S019UL-G3) and the corresponding calibrators were bought from Siemens (Siemens Nederland NV -Health sector, Den Haag, The Netherlands). Kanamycin sulphate (product no. K4000, batch no. SLBH1521V) was purchased from Sigma Aldrich (MO, USA). The actual content of kanamycin was calculated based on the molecular weight and was corrected for the water content. Ultrapure water was obtained from a Milli-Q system (Millipore Corporation, MA, USA). The used matrix was serum derived from unused blank blood donor retrieved from the blood bank (Sanquin, Amsterdam, The Netherlands).
A stock solution of kanamycin was prepared with a concentration of 100 mg/L in ultrapure water.
Method development
The original tobramycin calibration line spanned a concentration range of 0 -10 mg/L. We tested kanamycin in a concentration range of 0. 
Method validation
The complete application as programmed in the Architect is listed in table 1. Each concentration level without dilution steps (0.3 -10 mg/L, n = 7) was analysed on three consecutive days to determine the inaccuracy and imprecision. On each day, each concentration level was analysed in five-fold resulting in a total of 105 samples to be analysed. To assess the linearity, the data was fitted to linear, quadratic and cubic regression analysis. The average deviation of the best fitting model from linearity (ADL) was calculated. The limit of the ADL was 15% (based on a total error goal of 15%) 14 .
The bias (%) was calculated in comparison with the nominal concentration. This bias should be within 20% of the nominal concentration (LLOQ: 25%) 15 , since the immunoassay is a ligand binding assay. Furthermore, the within-day and between-day variance was determined by Oneway ANOVA. Between-day variance was tested for significance using a F-test. The within-run and between-run inaccuracy should be within 20% of the nominal value (LLOQ: 25%) 15 . In addition, the total error (sum of the absolute % relative error and the coefficient of variation (CV)) should be <30% (LLOQ: 40%).
Dilution integrity was assessed by diluting concentrations of 20 -80 mg/L following the described dilution protocol. All samples were diluted and analysed in five-fold on three consecutive days (75 samples in total). The bias was calculated and should be within 20% of the nominal concentration. The within-day and between-day variance also should be within 20% of the nominal value.
The stability of the QC samples was tested after one month of storage in the refrigerator at 2 -8 ˚C. The bias (%) in reference to the nominal concentration and variance in analytical result between day 0 and day 30 was tested using One-Way ANOVA and F-tests. The stability at both storage conditions was assessed in five-fold.
Cross-reactivity was determined with tobramycin. Kanamycin was analysed with the original tobramycin protocol in a concentration range of 0.3 -100 mg/L with 14 data points to evaluate cross-reactivity . Furthermore, cross-reactivity with a large variety of antimicrobials, antivirals and immunosuppressant drugs was tested. Interference due to endogenous substances has been evaluated by analysing random samples of patients (n=50) not receiving tobramycin or kanamycin treatment. In addition, we analysed five hemolytic, five lipemic and five icteric plasma samples to assess any matrix effect before spiking and after spiking with 0.5 mg/L kanamycin. The immunoassay autosampler was configured to use a standardized washing program, in which the needle was washed on the inside and outside as well as the cuvet. This washing program is normally used for many other analyses performed on the platform and carry-over effects are normally not observed and thus for the kanamycin assay not to be expected. Nevertheless, we evaluated the carry-over effect by analysing 100 mg/L kanamycin followed by a blank sample in quintuplicate.
Dilution integrity was tested in the inaccuracy and imprecision determination, since we diluted all the samples with a concentration >10 mg/L to be within the tobramycin calibration range.
LC-MS/MS comparison
Available serum patient samples with different concentrations kanamycin were analysed with the modified immunoassay method and a previously described LC-MS/MS method. 8 Paired analysis of anonymized patient samples with the two different analytical procedures was allowed without additional informed consent according to hospital regulations and Dutch Law.
The results of the two methods were evaluated by Passing and Bablok regression analysis. 16 
Statistics
Passing and Bablok statistics and the linearity evaluation were performed using Analyse-IT® software. A sample size analysis for the method comparison was performed at a concentration of 5 mg/L and a predicted coefficient of variation (CV) of 3%. This resulted in a minimum of 37 samples to detect the critical difference (0.5 mg/L) in both the slope and a the intercept at a range ratio of 10 17 . Plots) were constructed using SigmaPlot version 12 (Systat Software, Inc, CA, USA).
RESULTS
Method validation
The bias in the measured concentration in relation to the nominal concentration was <15% at all concentration levels in the range of 0.3 -10.0 mg/L (table 2). The coefficient of variation within-day and between-day ranged between 0.0 and 13.3%. The overall coefficient of variation was 17.4% at LLOQ and ranged from 3.9 -11.5% at 0.50 -10.0 mg/L (table 2). Table 2 . Accuracy and precision determination in the quantification of kanamycin. All concentrations were measured in five-fold on three consecutive days (n = 15). The dilution integrity results are also shown in table 2. The bias was calculated at -5.2 -1.4% with an overall CV of 3.7 -8.9% in the range of 20 -80 mg/L. In addition, no carry-over effect was observed.
Concentration
The correlation between the nominal concentrations and measured concentrations is displayed in figure 2 . The calibration curve was fitted to linear, quadratic and cubic regression models. The cubic regression model fitted best with a standard error (SE) of 0.27 (SE linear model: 0.29). Both X2 and X3 were different from 0 at the 5% significance level. However, the deviation from the linear regression line was considered not clinically relevant, since the calculated ADL was smaller than the ADL limit (0.11 vs. 0.15). There was no difference in absorption observed between the two tobramycin assay lots used (data not shown).
After storing the QC samples one month at 2 -8 ˚C in a refrigerator, the maximum bias was 9.7% compared to the nominal concentration (table 3). The maximum bias of fresh QC samples after one freeze-thaw cycle (-20 ˚C), was calculated at 8.1%. The tobramycin response was evaluated at different kanamycin concentrations ( figure 3) . At the highest kanamycin concentration of 100 mg/L, the tobramycin concentration was calculated to be 4.91 mg/L. Cross-reactivity for other antimicrobials, antivirals and immunosuppressant drugs are displayed in table 4 . All 50 patient samples tested, were below the limit of detection. Before spiking, the five haemolytic, icteric and lipemic samples were all below the limit of detection. After spiking, no measured concentrations differed more than ±15% from the nominal spiked concentration. The mean deviation was 6.4% (range: 2.0 -8.0%) for haemolytic samples, -0.8% (range: -8.0 -2.0%) for icteric samples and 3.6% (range: -6.0 -12.0%) for lipemic samples. 
LC-MS/MS comparison
In total, 44 patient serum samples were measured using both the LC-MS/MS method 8 and the modified immunoassay method. The relation between LC-MS/MS and immunoassay concentration was described by: immunoassay concentration = 0.21 (95% CI: -0.04 -0.53) + 0.97 (95% CI: 0.93 -1.02) x LC-MS/MS concentration (Passing and Bablok regression, figure 4 ). No significant deviation was observed from linearity (CUMSUM test for linearity, P > 0.1). A Bland-Altman plot is shown in figure 5 . 
DISCUSSION
Kanamycin is structurally similar to tobramycin and we have demonstrated that the commercially available tobramycin kit Syva Emit 2000 Tobramycin Assay is able to quantify serum concentrations of kanamycin. This would facilitate therapeutic drug monitoring of this aminoglycoside in the treatment of TB. We modified and validated the Syva Emit 2000 Tobramycin Assay method developed for tobramycin for the quantification of kanamycin in serum. This immunoassay is applicable to a large concentration range for kanamycin of 0.3 -80.0 mg/L and is therefore suitable for measuring both kanamycin serum trough and peak serum concentrations. The CV (%) and bias of this method are relatively small and complied with the FDA and EMA guidelines. In addition, the method complied also with the CLSI guidelines on imprecision, accuracy/trueness, carryover, dilutions, interferences and calibration standards. 18 Yet, the CLSI guidelines require that the assay should be evaluated for at least 20 days to ensure the robustness of the method over time. Our method included, however, daily QC controls to ensure the reliability of this method. If QC values are not within set limits the assay is recalibrated.
With aminoglycoside therapy, the C max divided by the MIC is the efficacy predicting parameter. However, monitoring and minimizing trough concentrations is also essential as this correlates with toxicity. 19 With this immunoassay method, both kanamycin C max concentrations up to 80.0 mg/L and low trough concentrations >0.3 mg/L can be quantified. This makes this method valuable for clinical practice.
The use of aminoglycosides is essential in MDR-TB treatment. 20 However, pharmacokinetic monitoring is essential in selecting the optimal dose. In a recent cohort, PK guided dosing resulted in a dose reduction of aminoglycosides from 15 mg/kg to 7.5 mg/kg in a MDR-TB cohort with a very high treatment success of 78.8%. 6 Also, monitoring peak-and trough serum concentrations has proven to be important since the cumulative AUC or cumulative dose is predictive for toxicity. 3, 4 One limitation of this method, and immunoassays in general, is cross-reactivity with other endogenous and exogenous compounds. However, the existing kit is designed and tested with haemolytic, icteric and lipemic blood samples and no significant interference was found 13 . Since the assay was adjusted in order to analyse kanamycin, we tested 50 patient samples without kanamycin to test for interference. No interference was observed, which indicates that this modified method is not prone to interference by endogenous substances. Another possible limitation is the systematic dilution performed by the Architect to quantify kanamycin >10 mg/L. However, the use of systemic dilutions is frequently used in immunoassays and the imprecision and inaccuracy of the entire dilution range is well within the defined ±15% limits.
In addition, we tested the cross-reactivity of a great variety of antimicrobials, antiretrovirals and immunosuppressants. As TB is frequently accompanied with HIV, the absence of cross reactivity with antiretrovirals is essential. Only a low and insignificant cross-reactivity with amikacin was observed, indicating that cross-reactivity is not to be expected in clinical practice. Moreover, a combination of amikacin and kanamycin is never used. 21 In addition, no matrix effects due to haemolytic, lipemic or icteric plasma matrices were observed.
Multiple methods for the quantification of kanamycin have been published. 8, 9, 11, [22] [23] [24] [25] Only one paper describes the use of an immunoassay for the determination of kanamycin, where a tobramycin antibody was used as well. 23 However, the antibody in that assay is, to our knowledge, not commercially available. Furthermore, the concentration range was limited to 40 mg/L kanamycin and the inaccuracy and imprecision were not assessed at concentrations < 5 mg/L. A high pressure liquid chromatography method has a rather high LLOQ of 3 mg/L 24 and inaccuracy and imprecision determinations according to the EMA or FDA guidelines were not reported. 15, 26 In addition, three LC-MS/MS methods are available, but these methods require expensive technology and experienced laboratory personnel. 8, 9, 11 Furthermore, we compared the modified immunoassay method with the LC-MS/MS method which was published earlier. 8 The 95% confidence interval of the Passing and Bablok regression equation included 0 in the intercept and 1 in the slope, indicating that both methods provided the same analytical result. 16 The specific immunoassay kit on the Architect platform used in this study shows crossreactivity to kanamycin and is therefore suitable in quantifying kanamycin. However, the ability of other similar immunoassay kits to quantify kanamycin is unknown. This could be a subject for further investigation. The analysis of kanamycin with a modified tobramycin assay, however, should always be thoroughly validated before clinical use.
The method has proven to be reliable, reproducible and shows no cross-reactivity with the compounds tested. This method of analysis for kanamycin can be implemented on any open analyser platform such as the Architect c8000 without the need for LC-MS/MS equipment to perform therapeutic drug monitoring of kanamycin in order to optimize TB treatment.
CONCLUSION
This method is capable of quantifying a large concentration range of kanamycin in a reliable and reproducible way. With this method, therapeutic drug monitoring of kanamycin is possible without the need of expensive and complex equipment such as LC-MS/MS.
